Multiple myeloma - PubMed (original) (raw)

Review

Multiple myeloma

R Bataille et al. N Engl J Med. 1997.

No abstract available

PubMed Disclaimer

Similar articles

• Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
  Hiyoshi M, Hashimoto S, Ota T, Nakao T, Takubo T, Tagawa S, Tatsumi N. Hiyoshi M, et al. Haematologia (Budap). 1997;28(3):177-80. Haematologia (Budap). 1997. PMID: 9283919
• Transient response of myeloma clone to pamidronate therapy.
  Corso A, Astori C, Orlandi E, Zappasodi P, Arcaini L, Bernasconi C. Corso A, et al. Haematologica. 1999 Aug;84(8):759-60. Haematologica. 1999. PMID: 10457421 No abstract available.
• Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
  Ararat E, Sahin I, Ozdemir E, Altundag K. Ararat E, et al. Br J Haematol. 2010 Dec;151(5):530-1. doi: 10.1111/j.1365-2141.2010.08388.x. Epub 2010 Sep 29. Br J Haematol. 2010. PMID: 20880117 No abstract available.
• New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
  Oken MM. Oken MM. Cancer. 1992 Aug 15;70(4 Suppl):946-8. Cancer. 1992. PMID: 1638466 Review.
• [Current therapy concepts in patients with multiple myeloma].
  Heyll A, Schneider P, Bauser U, Kobbe G, Hünerlitürkoglu A, Aul C, Haas R. Heyll A, et al. Dtsch Med Wochenschr. 2000 Oct 6;125(40):1201-9. doi: 10.1055/s-2000-7695. Dtsch Med Wochenschr. 2000. PMID: 11075253 Review. German. No abstract available.

Cited by

• 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
  Gao S, Dong F, Yang P, Chen Y, Wang Y, Wang J, Shi Y, Jing H. Gao S, et al. Ann Hematol. 2024 Jun;103(6):1979-1987. doi: 10.1007/s00277-023-05588-6. Epub 2024 Jan 11. Ann Hematol. 2024. PMID: 38206369
• The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.
  Wang Y, Xu J, Lan T, Zhou C, Liu P. Wang Y, et al. Cancer Med. 2023 Dec;12(24):21651-21665. doi: 10.1002/cam4.6721. Epub 2023 Nov 15. Cancer Med. 2023. PMID: 37965778 Free PMC article.
• Hyperammonemic Encephalopathy: A Rare Presentation of Relapsed Multiple Myeloma.
  Menakuru SR, Atta M, Ammannagari N, Younes M. Menakuru SR, et al. J Hematol. 2023 Jun;12(3):128-132. doi: 10.14740/jh1097. Epub 2023 Apr 30. J Hematol. 2023. PMID: 37435418 Free PMC article.
• Advanced Imaging in Multiple Myeloma: New Frontiers for MRI.
  Torkian P, Azadbakht J, Andrea Bonaffini P, Amini B, Chalian M. Torkian P, et al. Diagnostics (Basel). 2022 Sep 9;12(9):2182. doi: 10.3390/diagnostics12092182. Diagnostics (Basel). 2022. PMID: 36140583 Free PMC article. Review.
• Integrative Analysis of Gene Expression Through One-Class Logistic Regression Machine Learning Identifies Stemness Features in Multiple Myeloma.
  Ban C, Yang F, Wei M, Liu Q, Wang J, Chen L, Lu L, Xie D, Liu L, Huang J. Ban C, et al. Front Genet. 2021 Aug 16;12:666561. doi: 10.3389/fgene.2021.666561. eCollection 2021. Front Genet. 2021. PMID: 34484287 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information